50 jili ph Ipswich: Ed Sheeran helps sign player before performing with Taylor SwiftNone

Liminal, Microblink forecast 2025 trends in identity document verificationBethel High graduate Mike Davis helps players adjust when joining or leaving the Lakers' organization. "When you get to that facility, it's a basketball player and fan’s dream."

Ponipate Loganimasi [Source: World Rugby Sevens] It’s been quite a year for national rugby rep Ponipate Loganimasi after being named the Men’s Sevens Dream Team of the Year at the World Rugby Awards today. Loganimasi won a silver medal with the Fiji 7s side in Paris before making his Flying Fijians debut at the Pacific Nations Cup in Japan this year. He later signed a contract with the Fijian Drua for Super Rugby Pacific. Other players that made the World Rugby 7s Dream Team of the Year are Selvyn Davids from South Africa, Antoine Dupont and Aaron Grandidier Nkanang of France, Ireland’s Terry Kennedy, Nathan Lawson of Australia and Matías Osadczuk from Argentina. Meanwhile, Dupont also won the World Rugby Men’s 7s Player of the Year award while South Africa’s Pieter-Steph du Toit is the 15s Player of the Year. World Rugby Women’s 15s Player of the Year is Ellie Kildunne of England. Australia’s Maddison Levi won the Women’s Sevens Player of the Year award and All Blacks rookie Wallace Sititi is the Men’s 15s Breakthrough Player of the Year. World Rugby Women’s 15s Breakthrough Player of the Year is Erin King from Ireland.

I’ve heard of a coonskin cap, but this is ridiculous: A whale-watcher recently spotted an orca donning a dead salmon as a hat. What’s even more remarkable? The fashion statement appears to be the resurrection of a trend last seen in the orca community back in the ’80s. The salmon hat trend goes back to 1987, when a female in the Puget Sound was spotted with a dead salmon on her nose. According to Atlas Obscura , the fad spread throughout the female’s pod and over the next six weeks the trend was spotted among individuals in all three pods in the area. But shortly thereafter, the trend stopped. Thirty seven years later, it appears it may be rearing its ugly—er, fishy—head again. The stylish whale seen donning the salmon is J27 Blackberry, a member of the Puget Sound’s J pod. It was spotted with its fishy fashion statement on October 25. In an image snapped that day, the back end of the fish—on top of the mammal—is visible just above the water line. According to the Orca Conservancy, J27 Blackberry is a male born in 1991 that is “one of the most popular Southern Resident killer whales” and has a close relationship with his sister, J31, and younger brother, J39. The siblings lost their mother, J11, in 2008. “It’s true that orcas have social trends, and that in the late 1980s this particular group of orcas was observed to engage in a short-lived trend of ‘wearing’ dead salmon on their heads,” said Stephanie Raymond, a program manager for the Orca Network, in an email to Gizmodo. “More recently, a single photo of an adult male orca with a salmon perched on his head has sparked a firestorm of memes and media attention about the retro trend returning.” “If the salmon ‘wearing’ behavior exhibited by the whale known to local whale enthusiasts as J27 Blackberry was, in fact, a revival of the old trend, there would be ample documentation of that,” Raymond added. According to the marine conservation group ORCA , humpback whales are occasionally spotted with seaweed on their heads—perhaps because it feels good. But humpback whales don’t eat kelp, and orcas do eat salmon. So the recent spotting—even though it was only observed in one individual—is more equivalent to a human wearing spaghetti and meatballs on their head than, say, dental floss. These are heady days for an orca. Last year, the whales made headlines for attacking boats, and this year capsized a 49-foot yacht. This year, some of the apex predators were spotted hunting dolphins off the coast of Chile, one individual off South Africa ate a great white shark in two minutes, and another pod off Mexico learned to hunt whale sharks, the largest fish in the world. Because the trend resurfaced (no pun intended) in the Puget Sound—same as before—it’s possible that some of the individuals who experienced the fad the first time are involved with its resurgence, as one researcher told New Scientist . However, J27 Blackberry was only born four years after the trend was last seen, so it’s unclear how the behavior may have been adopted by the 33-year-old cetacean.Mutual of America Capital Management LLC cut its position in Blueprint Medicines Co. ( NASDAQ:BPMC – Free Report ) by 0.9% in the third quarter, HoldingsChannel.com reports. The firm owned 32,144 shares of the biotechnology company’s stock after selling 302 shares during the period. Mutual of America Capital Management LLC’s holdings in Blueprint Medicines were worth $2,973,000 as of its most recent SEC filing. Other hedge funds have also modified their holdings of the company. Hsbc Holdings PLC bought a new position in shares of Blueprint Medicines during the 2nd quarter worth approximately $1,060,000. Comerica Bank lifted its holdings in shares of Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock valued at $1,028,000 after purchasing an additional 10,435 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Blueprint Medicines by 27.8% in the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after purchasing an additional 13,579 shares in the last quarter. SG Americas Securities LLC grew its stake in Blueprint Medicines by 82.8% during the 2nd quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company’s stock worth $2,337,000 after buying an additional 9,819 shares during the last quarter. Finally, Nicholas Investment Partners LP acquired a new position in Blueprint Medicines during the 2nd quarter valued at about $4,377,000. Blueprint Medicines Price Performance Shares of NASDAQ BPMC opened at $94.15 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The firm’s 50 day simple moving average is $90.36 and its 200-day simple moving average is $98.53. Blueprint Medicines Co. has a 12 month low of $66.61 and a 12 month high of $121.90. The stock has a market capitalization of $5.98 billion, a price-to-earnings ratio of -44.62 and a beta of 0.59. Analysts Set New Price Targets Several equities research analysts have weighed in on the company. Barclays raised their price target on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a report on Monday, July 29th. Wedbush reissued an “outperform” rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Thursday, November 14th. JPMorgan Chase & Co. initiated coverage on shares of Blueprint Medicines in a report on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price target for the company. Baird R W upgraded shares of Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, Guggenheim upped their target price on Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.11. View Our Latest Research Report on BPMC Insider Activity In other news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the transaction, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website . Insiders own 4.21% of the company’s stock. About Blueprint Medicines ( Free Report ) Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. Further Reading Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. ( NASDAQ:BPMC – Free Report ). Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter .